Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by Frictionon Oct 03, 2000 6:21pm

315 Views

Post# 2598488

RE: Investor Relations and no reply from them

I think it depends on the nature of your inquiry. I presume they get a fair amount of questions ranging from when will the next nr be, to share price predictions. I asked a question of the IR dept and received a prompt reply that the question was being forwarded to the ceo.

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects